WEKO3
アイテム
{"_buckets": {"deposit": "60491ff9-c8f6-48e2-a01f-16e5f51f369d"}, "_deposit": {"id": "20229", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "20229"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00020229", "sets": ["462"]}, "author_link": ["106685", "106686", "106687", "106688", "106689", "106690", "106691", "106692", "106693", "106694", "106695"], "item_1628147817048": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_6_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2015-09-26", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "5", "bibliographicPageEnd": "1004", "bibliographicPageStart": "997", "bibliographicVolumeNumber": "76", "bibliographic_titles": [{"bibliographic_title": "CANCER CHEMOTHERAPY AND PHARMACOLOGY"}]}]}, "item_6_description_20": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Purpose\u003cbr/\u003eIpilimumab is designed to block cytotoxic T-lymphocyte antigen-4 to augment antitumor T cell responses. In studies of predominantly Caucasian patients with advanced melanoma, ipilimumab was associated with durable response, long-term survival benefit, and a manageable safety profile. This phase II study assessed the safety of ipilimumab in Japanese patients with unresectable stage III or IV melanoma.\u003cbr/\u003eMethods\u003cbr/\u003ePatients received ipilimumab 3 mg/kg every 3 weeks for four doses. The database lock for the original analysis was in August 2014. Overall survival, progression-free survival, and data on deaths were based on an updated, follow-up analysis (database lock April 2015).\u003cbr/\u003eResults\u003cbr/\u003eData are reported from 20 patients. Fifteen patients (75 %) received all four doses of ipilimumab during induction. Twelve patients (60 %) had at least one drug-related adverse event (AE), and no patients discontinued due to a drug-related AE. There were no deaths related to study drug. The most common drug-related AEs were rash (n = 7), pyrexia (n = 3), increased aspartate aminotransferase (AST; n = 3), and increased alanine aminotransferase (ALT; n = 3). Twelve patients (60 %) reported immune-related AEs (irAEs); most frequent were skin (n = 9) and liver (n = 3) disorders. Grade 3 irAEs were ALT and AST elevation (n = 2) and diabetes mellitus (n = 1). Two patients had a partial response and two had stable disease, yielding a 20 % disease control rate. Median overall survival and progression-free survival were 8.71 and 2.74 months, respectively.\u003cbr/\u003eConclusion\u003cbr/\u003eIpilimumab 3 mg/kg had a manageable AE profile in this Japanese patient population with clinical outcomes similar to that in Caucasian patients.", "subitem_description_type": "Abstract"}]}, "item_6_description_30": {"attribute_name": "資源タイプ(コンテンツの種類)", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_description_5": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "CANCER CHEMOTHERAPY AND PHARMACOLOGY.76(5):997-1004(2015)", "subitem_description_type": "Other"}]}, "item_6_link_3": {"attribute_name": "信州大学研究者総覧へのリンク", "attribute_value_mlt": [{"subitem_link_text": "Okuyama, Ryuhei", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.ZpfNHFSF.html"}]}, "item_6_link_67": {"attribute_name": "WoS", "attribute_value_mlt": [{"subitem_link_text": "Web of Science", "subitem_link_url": "http://gateway.isiknowledge.com/gateway/Gateway.cgi?\u0026GWVersion=2\u0026SrcAuth=ShinshuUniv\u0026SrcApp=ShinshuUniv\u0026DestLinkType=FullRecord\u0026DestApp=WOS\u0026KeyUT=000363245800013"}]}, "item_6_publisher_4": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "SPRINGER"}]}, "item_6_relation_47": {"attribute_name": "PubMed", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "26410424"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.ncbi.nlm.nih.gov/pubmed/26410424", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1007/s00280-015-2873-x"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1007/s00280-015-2873-x", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_62": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made."}]}, "item_6_select_64": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0344-5704", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0344-5704", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_40": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00598397", "subitem_source_identifier_type": "NCID"}]}, "item_6_text_69": {"attribute_name": "wosonly authkey", "attribute_value_mlt": [{"subitem_text_value": "Ipilimumab; Immune-checkpoint inhibitor; Melanoma; Phase II study; Japanese patients"}]}, "item_6_text_70": {"attribute_name": "wosonly keywords", "attribute_value_mlt": [{"subitem_text_value": "REGULATORY T-CELLS; ANTI-CTLA-4 ANTIBODIES; METASTATIC MELANOMA; ADVERSE EVENTS; CANCER-IMMUNOTHERAPY; ANTITUMOR-ACTIVITY; BLOCKADE; MANAGEMENT; NIVOLUMAB; EFFICACY"}]}, "item_6_textarea_68": {"attribute_name": "wosonly abstract", "attribute_value_mlt": [{"subitem_textarea_value": "Ipilimumab is designed to block cytotoxic T-lymphocyte antigen-4 to augment antitumor T cell responses. In studies of predominantly Caucasian patients with advanced melanoma, ipilimumab was associated with durable response, long-term survival benefit, and a manageable safety profile. This phase II study assessed the safety of ipilimumab in Japanese patients with unresectable stage III or IV melanoma. \u003cbr/\u003ePatients received ipilimumab 3 mg/kg every 3 weeks for four doses. The database lock for the original analysis was in August 2014. Overall survival, progression-free survival, and data on deaths were based on an updated, follow-up analysis (database lock April 2015). \u003cbr/\u003eData are reported from 20 patients. Fifteen patients (75 %) received all four doses of ipilimumab during induction. Twelve patients (60 %) had at least one drug-related adverse event (AE), and no patients discontinued due to a drug-related AE. There were no deaths related to study drug. The most common drug-related AEs were rash (n = 7), pyrexia (n = 3), increased aspartate aminotransferase (AST; n = 3), and increased alanine aminotransferase (ALT; n = 3). Twelve patients (60 %) reported immune-related AEs (irAEs); most frequent were skin (n = 9) and liver (n = 3) disorders. Grade 3 irAEs were ALT and AST elevation (n = 2) and diabetes mellitus (n = 1). Two patients had a partial response and two had stable disease, yielding a 20 % disease control rate. Median overall survival and progression-free survival were 8.71 and 2.74 months, respectively. \u003cbr/\u003eIpilimumab 3 mg/kg had a manageable AE profile in this Japanese patient population with clinical outcomes similar to that in Caucasian patients. "}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Yamazaki, N.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "106685", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kiyohara, Y.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "106686", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Uhara, H.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "106687", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukushima, S.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "106688", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Uchi, H.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "106689", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shibagaki, N.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "106690", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsutsumida, A.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "106691", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshikawa, S.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "106692", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okuyama, R.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "106693", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Y.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "106694", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tokudome, T.", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "106695", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-10-31"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Yamazaki2015_Article_PhaseIIStudyOfIpilimumabMonoth.pdf", "filesize": [{"value": "462.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensefree": "© The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.", "licensetype": "license_note", "mimetype": "application/pdf", "size": 462500.0, "url": {"label": "Yamazaki2015_Article_PhaseIIStudyOfIpilimumabMonoth.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/20229/files/Yamazaki2015_Article_PhaseIIStudyOfIpilimumabMonoth.pdf"}, "version_id": "fc3022ea-a84e-410c-bc5a-6ab5500b242e"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Ipilimumab", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Immune-checkpoint inhibitor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Melanoma Phase II study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Japanese patients ", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "1", "path": ["462"], "permalink_uri": "http://hdl.handle.net/10091/00020987", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2018-10-31"}, "publish_date": "2018-10-31", "publish_status": "0", "recid": "20229", "relation": {}, "relation_version_is_last": true, "title": ["Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma"], "weko_shared_id": -1}
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
http://hdl.handle.net/10091/00020987
http://hdl.handle.net/10091/000209879186c006-4404-43f0-a439-f29ee9b10488
名前 / ファイル | ライセンス | アクション |
---|---|---|
Yamazaki2015_Article_PhaseIIStudyOfIpilimumabMonoth.pdf (462.5 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-10-31 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題 | Ipilimumab, Immune-checkpoint inhibitor, Melanoma Phase II study, Japanese patients | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
著者 |
Yamazaki, N.
× Yamazaki, N.× Kiyohara, Y.× Uhara, H.× Fukushima, S.× Uchi, H.× Shibagaki, N.× Tsutsumida, A.× Yoshikawa, S.× Okuyama, R.× Ito, Y.× Tokudome, T. |
|||||
信州大学研究者総覧へのリンク | ||||||
氏名 | Okuyama, Ryuhei | |||||
URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.ZpfNHFSF.html | |||||
出版者 | ||||||
出版者 | SPRINGER | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | CANCER CHEMOTHERAPY AND PHARMACOLOGY.76(5):997-1004(2015) | |||||
書誌情報 |
CANCER CHEMOTHERAPY AND PHARMACOLOGY 巻 76, 号 5, p. 997-1004, 発行日 2015-09-26 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Purpose<br/>Ipilimumab is designed to block cytotoxic T-lymphocyte antigen-4 to augment antitumor T cell responses. In studies of predominantly Caucasian patients with advanced melanoma, ipilimumab was associated with durable response, long-term survival benefit, and a manageable safety profile. This phase II study assessed the safety of ipilimumab in Japanese patients with unresectable stage III or IV melanoma.<br/>Methods<br/>Patients received ipilimumab 3 mg/kg every 3 weeks for four doses. The database lock for the original analysis was in August 2014. Overall survival, progression-free survival, and data on deaths were based on an updated, follow-up analysis (database lock April 2015).<br/>Results<br/>Data are reported from 20 patients. Fifteen patients (75 %) received all four doses of ipilimumab during induction. Twelve patients (60 %) had at least one drug-related adverse event (AE), and no patients discontinued due to a drug-related AE. There were no deaths related to study drug. The most common drug-related AEs were rash (n = 7), pyrexia (n = 3), increased aspartate aminotransferase (AST; n = 3), and increased alanine aminotransferase (ALT; n = 3). Twelve patients (60 %) reported immune-related AEs (irAEs); most frequent were skin (n = 9) and liver (n = 3) disorders. Grade 3 irAEs were ALT and AST elevation (n = 2) and diabetes mellitus (n = 1). Two patients had a partial response and two had stable disease, yielding a 20 % disease control rate. Median overall survival and progression-free survival were 8.71 and 2.74 months, respectively.<br/>Conclusion<br/>Ipilimumab 3 mg/kg had a manageable AE profile in this Japanese patient population with clinical outcomes similar to that in Caucasian patients. | |||||
資源タイプ(コンテンツの種類) | ||||||
内容記述タイプ | Other | |||||
内容記述 | Article | |||||
ISSN | ||||||
収録物識別子タイプ | PISSN | |||||
収録物識別子 | 0344-5704 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00598397 | |||||
PubMed | ||||||
識別子タイプ | PMID | |||||
関連識別子 | https://www.ncbi.nlm.nih.gov/pubmed/26410424 | |||||
関連名称 | 26410424 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1007/s00280-015-2873-x | |||||
関連名称 | 10.1007/s00280-015-2873-x | |||||
権利 | ||||||
権利情報 | © The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. | |||||
出版タイプ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
WoS | ||||||
表示名 | Web of Science | |||||
URL | http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000363245800013 |